Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

Association between respiratory and herpes viruses on pulmonary exacerbations in cystic fibrosis patients

Simone Scheithauer a,⁎, Gerhard Haase b, Martin Häusler c, Sebastian Lemmen a, Klaus Ritter b,d, Michael Kleines d

a Department of Infection Control and Infectious Diseases, University Hospital RWTH Aachen, Germany
b Department of Medical Microbiology, University Hospital RWTH Aachen, Germany
c Department of Pediatrics, University Hospital RWTH Aachen, Germany
d Division of Virology, Department of Medical Microbiology, University Hospital RWTH Aachen, Germany

Received 10 December 2009; received in revised form 4 February 2010; accepted 7 February 2010
Available online 2 March 2010

Abstract

Respiratory viruses discovered in the 21st century and human herpes viruses (N=13) were seldom (4/50) detected in our cystic fibrosis patients although exacerbation frequency (7.75±2.9/a versus 4.45± 2.1/a; p=0.03) and colonization with Aspergillus fumigatus (RR: 2.6; CI95: 1.8–3.7), Pseudomonas aeruginosa (RR: 1.84; CI95: 1.4–2.4), and Staphylococcus aureus (RR: 1.5; CI95: 1.2–1.9) including MRSA (RR: 4.6; CI95: 1.3–16.6) were associated with virus positivity. Further studies should clarify whether this finding reflects non-specific colonization (human Bocavirus) or reactivation (Epstein-Barr virus) or rather an acceleration of lung tissue inflammation.

© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Keywords: Infection; Exacerbation; Emerging viruses; Herpesvirus

1. Background

Respiratory infections caused by common respiratory viruses are associated with an increase in morbidity in patients with cystic fibrosis (CF) [1–3]. The role of novel respiratory viruses (RVs) and human herpes viruses (HHVs) for acute pulmonary exacerbations in CF patients is currently unknown.

2. Methods

This prospective study investigated the role of eight novel RVs and five HHVs in patients with CF. Detailed patients’ characteristics, clinical disease patterns, as well as pulmonary bacterial and fungal colonization patterns in the CF patients were included in order to conduct a risk factor analysis.

⁎ Corresponding author. Department of Infection Control and Infectious Diseases, Center for Infectious Diseases (DGI), University Hospital Aachen, RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany. Tel.: +49 241 8035036; fax: +49 241 8082540.
E-mail address: sscheithauer@ukaachen.de (S. Scheithauer).

Received 10 December 2009; received in revised form 4 February 2010; accepted 7 February 2010
Available online 2 March 2010

Respiratory specimens (sputum) consecutively sampled at the University Hospital Aachen from 07/07 to 06/08 of 50 CF patients were analyzed by nucleic acid amplification technologies (PCR; RT-PCR) for the presence of 13 viruses (human Cytomegalovirus, Epstein-Barr virus (EBV), Herpes simplex virus 1+2, Varicella zoster virus, human bocavirus (HBoV), human coronaviruses (229E, OC43, HKU1, NL63), human metapneumovirus, and human polyomaviruses (KIPyV, WUPyV)). Specimens were obtained routinely (2/3) and during exacerbation (1/3). For a summary of the key characteristics of the CF patients, see Table 1.

Clinical and microbial colonization data of the patients were analyzed statistically using the Mann–Whitney U test; for associations the risk ratios (RR) including 95% confidence intervals were given.

3. Results

HBoV DNA was detected in 1 patient (2%) and EBV DNA in 3 patients (6%) resulting in a positivity rate of 8%. Viral loads were 1.5×10E2 genome equivalents (geq)/ml for HBoV and
Table 1
Characteristics of the CF patients (N=50).

| Parameter                        | Mean±SD (range) |
|----------------------------------|-----------------|
| Age (years)                      | 25±12 (1–67)    |
| Height (m)                       | 1.68±0.1 (1.18–1.88) |
| Weight (kg)                      | 60±16 (20–140)  |
| BMI*                             | 21.3±5.5 (14.4–52.1) |
| Shwachman Score                  | 60±13 (40–75)   |
| FEV-1 (l)                        | 2.1±1.0 (0.47–4.20) |

Table 2
Clinical and microbial data of the CF patients.

| Parameter                        | Virus-negative patients (n=46) | Virus-positive patients (n=4) | Associations/ differences |
|----------------------------------|--------------------------------|------------------------------|--------------------------|
| Age (range)                      | 25±12 (1–68)                   | 19±8 (11–29)                 | ns*                      |
| Gender (m:f)                     | 25:21                         | 3:1                          | ns*                      |
| Exacerbations/year (SD)          | 4.45 (±2.9)                   | 7.75 (±2.1)                  | p=0.03*                  |
| Colonization (%) with            |                                |                              |                          |
| S. aureus                        | 30 (65%)                      | 4 (100%)                     | RR*: 1.53 (CI95: 1.24–1.89) |
| Ps. aeruginosa                   | 25 (54%)                      | 4 (100%)                     | RR*: 1.84 (CI95: 1.41–2.40) |
| Enterobacteriaceae               | 15 (33%)                      | 0 (0%)                       | ns*                      |
| H. influenza                     | 9 (20%)                       | 0 (0%)                       | ns*                      |
| Alcaligenaceae                   | 9 (20%)                       | 0 (0%)                       | ns*                      |
| S. maltophilia                   | 7 (15%)                       | 0 (0%)                       | ns*                      |
| Aspergillus fumigatus            | 18 (39%)                      | 4 (100%)                     | RR*: 2.56 (CI95: 1.78–3.66) |
| Shwachman Score                  | 60 (±13)                      | 61 (±13)                     | ns*                      |
| BMI                              | 21 (5.6)                      | 21 (3.5)                     | ns*                      |
| Mutation: not dF508/ dF508       | 49 (41%)                      | 3 (75%)                      | ns*                      |
| or dF508/ R553X                  |                               |                              |                          |
| Mutation: not dF508/ R553X       | 1 (2%)                        | 1 (25%)                      | ns*                      |
| or R553X/ dF508                  |                               |                              |                          |
| ABPA c                          | 5 (11%)                       | 1 (25%)                      | ns*                      |
| D. mellitus and/or              | 13 (28/11%)                   | 0 (0/0%)                     | ns*                      |
| D. insipidus                    |                               |                              |                          |
| Pancreatic insufficiency         | 42 (91%)                      | 4 (100%)                     | ns*                      |

* BMI: body mass index.
* FEV-1: forced expiratory volume.
* Data available only for 49 patients.
* ABPA: allergic bronchopulmonary aspergillosis.
* DIOS: distal intestinal obstructive syndrome.
* OTLT: orthotopic liver transplantation.

Patients only tested positive for 2 of the 13 viruses (HBoV = 1, EBV = 3). This detection rate of 8% is known to be similarly low in non-CF patients indicating that the 13 viruses tested for do not frequently account for most pulmonary exacerbations in patients with CF [6,8]. Retrospective studies report that HBoV is most prevalent in infants up to the age of 2 years [7]. It should also be borne in mind that most of respiratory virus infections occur during childhood and therefore, age may be the most important risk factor [6,9]. Thus, as our cohort consisted of mostly adults, we cannot exclude the possibility that age effects may have biased our results. Previous investigations demonstrated a higher frequency of pulmonary exacerbations for common respiratory viruses like RSV [1,4,10]. In line with these results, we found that the pulmonary exacerbation frequency was significantly associated with virus positivity in this study. However, we did not detect any deterioration of the Shwachman Score or a decline of FEV1 as shown for common respiratory viruses [1,4,10,11]. Moreover, our results indicate an association of virus positivity with colonization by A. fumigatus, P. aeruginosa, and Staphylococcus species (including MRSA). For other well-known respiratory viruses, an association with several of the same bacterial pathogens has been previously suggested [1,11,12]. A limitation is the small number of CF patients participating in our study. Further studies ranged from 1 x 10E3 geq/ml to 9 x 10E4 geq/ml for EBV. Interestingly, patients tested positive for viral DNA had suffered significantly more pulmonary exacerbations during the preceding year (7.75, SD: 2.06 vs. 4.45, SD: 2.92; p = 0.03). Furthermore, all four virus-positive patients were colonized with Aspergillus fumigatus (RR: 2.56; CI95: 1.78–3.66), Pseudomonas aeruginosa (RR: 1.84; CI95: 1.41–2.40), and Staphylococcus aureus (RR: 1.53; CI95: 1.24–1.89) and these patients were significantly more often positive for MRSA (RR: 4.6; CI95: 1.28–16.59). For further clinical and microbial data of the CF patients, see Table 2.

4. Conclusions

Common respiratory viruses like respiratory syncytial virus (RSV), influenza viruses, and adenoviruses have been shown to increase morbidity in CF patients [1]. Although CF patients do not contract respiratory infections any more frequently than patients without CF, when they do, these infections seem to have a greater impact on morbidity of CF patients compared to patients without CF [1,4,5]. During the last decade, HHVs were increasingly recognized as respiratory pathogens and since then several novel RVs have been discovered [6]. However, these novel viruses play a pathogenic or passenger role in regards to respiratory diseases is still an ongoing debate [7].
should clarify whether our findings reflect a non-specific colonization (HBoV) or reactivation (EBV) in an otherwise severely infected organ or if these viral infections worsen lung tissue inflammation and thus accelerate the progression of lung disease in CF.

Results were partly presented at the 61st Annual Meeting of the German Society of Microbiology and Hygiene (DGHM) in Göttingen, Germany (20–23 September 2009)[13].

Acknowledgements

Thanks go to the Aachener CF-Ambulanzen, Kinderarzt-praxis Laurensberg & Erwachsenenambulanz Luisenhospital.

This study was supported by an EU grant to M.K. (Contract no. 037276).

References

[1] van Ewijk BE, van der Zalm MM, Wolfs TF, der Ent CK. Viral respiratory infections in cystic fibrosis. J Cyst Fibros 2005;4(Suppl 2):31–6.
[2] Olesen HV, Nielsen LP, Schlotz PO. Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatr Pulmonol 2006;41:1197–204.
[3] Wat D. Impact of respiratory viral infections on cystic fibrosis. Postgrad Med J 2003;79:201–3.
[4] Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984;311:1653–8.
[5] Ramsey BW, Gore EJ, Smith AL, Cooney MK, Redding GJ, Foy H. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child 1989;143:662–8.
[6] Osterhaus AD. New respiratory viruses of humans. Pediatr Infect Dis J 2008;27(10 Suppl):S71–4.
[7] Schildgen O, Müller A, Allander T, Mackey IM, Völz S, Kupfer B, Simon A. Human bocavirus: passenger or pathogen in acute respiratory tract infections? Clin Microbiol Rev 2008;21:291–304.
[8] Sloots TP, Whiley DM, Lambrecht SP, Nissen MD. Emerging respiratory agents: new viruses for old diseases? J Clin Virol 2008;42:233–43.
[9] Armstrong D, Grinwood K, Carlin JB, Carzino R, Hull J, Olinsky A, et al. Severe viral respiratory infections in infants with cystic fibrosis. Ped Pulmonol 1998;26:371–9.
[10] Winnie GB, Cowan RG. Association of Epstein-Barr virus infection and pulmonary exacerbations in patients with cystic fibrosis. Pediatr Infect Dis J 1992;11:722–6.
[11] Collinson J, Nicholson KG, Cancio E, Ashman J, Ireland DC, Hammersley V, Kent J, O’Callaghan C. Effects of upper respiratory tract infections with pulmonary deterioration in patients with cystic fibrosis. Thorax 1996;51:1115–22.
[12] Johansen HK, Hoiby N. Seasonal onset of initial colonization and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992;47:109–11.
[13] Scheithauer S, Haase G, Häusler M, et al. Impact of emerging respiratory viruses and herpesviruses on pulmonary exacerbations in cystic fibrosis [abstract]. JIMM 2009;299(Suppl1):74.